Published in Br J Cancer on June 05, 2002
Reproducibility of serum cytokines and growth factors. Cytokine (2008) 1.61
Detectability and reproducibility of plasma levels of chemokines and soluble receptors. Results Immunol (2013) 0.85
Vascular endothelial growth factor and breast cancer risk. Cancer Causes Control (2008) 0.81
Does the timing of breast cancer surgery in pre-menopausal women affect clinical outcome? An update. Int Semin Surg Oncol (2006) 0.79
A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes Control (2016) 0.75
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet (1991) 4.09
Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer (1998) 3.93
Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A (1997) 3.30
Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol (1992) 2.72
Serum vascular endothelial growth factor levels in various liver diseases. Dig Dis Sci (1998) 1.91
Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res (1996) 1.81
Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res (1997) 1.74
Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) (1998) 1.46
Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res (1998) 1.44
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res (1996) 1.39
Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol (1995) 1.35
Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res (1998) 1.29
Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer (1997) 1.16
Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology (1996) 1.11
Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab (1998) 1.00
Strongly enhanced serum levels of vascular endothelial growth factor (VEGF) after polytrauma and burn. Clin Chem Lab Med (1998) 0.91
Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? Br J Cancer (1998) 0.89
Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. Int J Mol Med (1998) 0.84
Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet (2003) 6.15
Relation between socioeconomic deprivation and pathological prognostic factors in women with breast cancer. BMJ (1994) 4.39
Screening for breast cancer. Br Med J (1976) 4.23
Psychological support for patients undergoing breast cancer surgery: a randomised study. BMJ (1996) 4.11
Acceptors and rejectors of an invitation to undergo breast screening compared with those who referred themselves. J Epidemiol Community Health (1980) 2.95
Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet (1996) 2.78
Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) (1981) 2.14
Gynaecological monitoring during tamoxifen therapy. Lancet (1994) 2.10
Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer (2006) 1.73
Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer (1996) 1.64
Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer (2006) 1.48
Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer (2012) 1.44
The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer (2012) 1.44
Thrombocytopenia with absent radii (TAR) syndrome: a new increased cellular radiosensitivity syndrome. Clin Oncol (R Coll Radiol) (1995) 1.40
In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer. Thromb Haemost (1989) 1.39
The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer (1991) 1.35
Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet (1983) 1.35
Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery (1995) 1.31
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol (1990) 1.25
Breast-conserving surgery and tumour bed positivity in patients with breast cancer. Br J Surg (1994) 1.23
Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer (2007) 1.21
Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer (1993) 1.20
Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet (1984) 1.18
A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer (2010) 1.18
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer (2009) 1.17
Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer (1995) 1.16
Anastomotic leaks in colorectal cancer surgery: a risk factor for recurrence? Int J Colorectal Dis (1991) 1.15
Early postoperative contrast radiology in the assessment of colorectal anastomotic integrity. Int J Colorectal Dis (1992) 1.13
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer (2008) 1.10
Randomized clinical trial of no wound drains and early discharge in the treatment of women with breast cancer. Br J Surg (2002) 1.10
Psychological morbidity in the first year after breast surgery. Eur J Surg Oncol (1992) 1.07
Drill biopsy in the diagnosis of breast cancer. Clin Oncol (1975) 1.05
Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst (1995) 1.05
Colostomy: the consequences of surgery. Clin Oncol (1976) 1.05
Breast reconstruction in the United Kingdom and Ireland. Br J Surg (2002) 1.05
Warfarin inhibition of metastasis: the role of anticoagulation. Br J Surg (1987) 1.04
Arteriovenous shunting of microspheres in patients with colorectal liver metastases: errors in assessment due to free pertechnetate, and the effect of angiotensin II. Nucl Med Commun (1987) 1.02
Immediate breast reconstruction does not lead to a delay in the delivery of adjuvant chemotherapy. Eur J Surg Oncol (2004) 1.02
Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. Br J Cancer (1992) 1.01
Possible test for selection of adjuvant systemic therapy in early cancer of the breast. Br J Surg (1980) 0.99
Putative markers for the detection of breast carcinoma cells in blood. Br J Cancer (1998) 0.98
Expression of gap junction proteins connexin 26 and connexin 43 in normal human breast and in breast tumours. J Pathol (1998) 0.97
Flow cytometric analysis of cell surface carbohydrates in metastatic human breast cancer. Br J Cancer (1990) 0.96
Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer (1990) 0.96
Recurrence of colorectal cancer after sutured and stapled large bowel anastomoses. Br J Surg (1991) 0.94
Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol (1996) 0.94
Ten-year follow-up of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg (2012) 0.93
The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast. Br J Cancer (1991) 0.93
Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. BMJ (2000) 0.93
Stercoral perforation with verapamil. Postgrad Med J (1994) 0.91
Role of non-medical staff in screening for breast cancer. Br Med J (1980) 0.90
Pre-operative determination of oestrogen receptor status in breast cancer by immunocytochemical staining of fine needle aspirates. Br J Surg (1985) 0.90
Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth. Br J Cancer (1989) 0.90
Anastomotic suture materials and implantation metastasis: an experimental study. Br J Surg (1989) 0.90
Intrasplenic hepatocyte transplantation in rats with experimental liver injury: morphological and morphometric studies. J Pathol (1989) 0.90
A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Recent Results Cancer Res (1984) 0.89
Angiographic embolization of the distal internal mammary artery as an adjunct to regional chemotherapy in inoperable breast carcinoma. J Vasc Interv Radiol (1995) 0.88
Single photon emission computed tomographic studies (SPECT) of hepatic arterial perfusion scintigraphy (HAPS) in patients with colorectal liver metastases: improved tumour targetting by microspheres with angiotensin II. Nucl Med Commun (1987) 0.88
Morphological and cell kinetic effects of dietary manipulation during colorectal carcinogenesis. Gut (1987) 0.88
Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy. Cancer Chemother Pharmacol (1990) 0.87
Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients. Cancer Lett (1992) 0.87
Use of boost radiotherapy in oncoplastic breast-conserving surgery - a systematic review. Eur J Surg Oncol (2013) 0.86
Hospital work load produced by breast-cancer screening programme run by trained non-medical staff. Br Med J (1980) 0.86
T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients. Immunol Lett (1992) 0.86
Experimental colorectal cancer: the relationship of diet and faecal bile acid concentration to tumour induction. Br J Surg (1986) 0.85
Long-term prognostic significance of thymidine labelling index in primary breast cancer. Eur J Cancer (1992) 0.85
Gastric emptying of a solid meal after long and short pyloroplasties. Br J Surg (1973) 0.85
Oncoplastic breast conservation does not lead to a delay in the commencement of adjuvant chemotherapy in breast cancer patients. Eur J Surg Oncol (2013) 0.84
Margin assessment by cavity shaving after breast-conserving surgery: analysis and follow-up of 543 patients. Eur J Surg Oncol (1999) 0.84
Local recurrence after breast-conserving surgery for breast cancer. Br J Surg (1996) 0.84
Preoperative mammographic features predict clinicopathological risk factors for the development of local recurrence in breast cancer. Breast (2000) 0.84
Comparison of breast cancer mortality rates with those of ovarian and colorectal carcinoma. Br J Surg (2007) 0.84
Evaluation of luteal-phase salivary progesterone levels in women with benign breast disease or primary breast cancer. Eur J Cancer Clin Oncol (1985) 0.84
Does deprivation affect breast cancer management? Br J Cancer (2005) 0.84
Optimum number of core biopsies for accurate assessment of histological grade in breast cancer. Br J Surg (2002) 0.84
Predicting local recurrence by correlating pre-operative mammographic findings with pathological risk factors in patients with breast cancer. Br J Radiol (1995) 0.84
The use of telomere biology to identify and develop superior nitrone based anti-oxidants. Biochem Biophys Res Commun (2006) 0.83
Semiquantitative analyses of fine needle aspirates from benign and malignant breast lesions. J Clin Pathol (1989) 0.83
The relationship between deprivation, tumour stage and the systemic inflammatory response in patients with primary operable breast cancer. Br J Cancer (2004) 0.82
Vocal fold paralysis following carotid endarterectomy. J Laryngol Otol (1999) 0.81
Serum progesterone concentration during the luteal phase in women with benign breast disease. Eur J Cancer Clin Oncol (1984) 0.81
Altered lymphocyte populations in tumour invaded nodes of breast cancer patients. Immunol Lett (1993) 0.80
Promotion of metastasis by a specific complex of coagulation factors may be independent of fibrin formation. Br J Cancer (1988) 0.80
Cystosarcoma phylloides: heterogeneity in a rare tumour type. J R Coll Surg Edinb (1996) 0.80
Increased proliferative activity and p53 expression in normal glandular breast tissue after radiation therapy. J Pathol (1998) 0.80
Tumour bed positivity predicts outcome after breast-conserving surgery. Br J Surg (1997) 0.79
Re: Inequalities in breast cancer reconstructive surgery according to social and locational status in Western Australia. Eur J Surg Oncol (2003) 0.79
Loss of heterozygosity on chromosome 7q31 in breast cancer. Lancet (1993) 0.79
Male mastectomy: an oncoplastic solution to improve aesthetic appearance. J Plast Reconstr Aesthet Surg (2013) 0.79
Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. Br J Surg (1992) 0.79
Chemical lumbar sympathectomy revisited: survey of the current practice of vascular surgeons in Scotland. Eur J Surg (2000) 0.79
Pancreatic-derived pathfinder cells enable regeneration of critically damaged adult pancreatic tissue and completely reverse streptozotocin-induced diabetes. Rejuvenation Res (2011) 0.78
Influence of tumour bed assessment on local recurrence following breast-conserving surgery for breast cancer. Eur J Surg Oncol (1999) 0.78
Weaning from mechanical ventilation in a general rehabilitation center: a commentary. Am J Phys Med Rehabil (1999) 0.78
Haemostatic abnormalities and outcome in patients with operable breast cancer. Eur J Cancer (1990) 0.78